This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

This study has been completed.
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
NCT00417833
First received: January 3, 2007
Last updated: October 17, 2008
Last verified: October 2008
  Purpose

Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG).

Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.


Condition Intervention Phase
Diabetic Proliferative Retinopathy Vascular Vein Oclussion Choroidal Neovascularization Drug: Intravitreal Bevacizumab Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)

Resource links provided by NLM:


Further study details as provided by Asociación para Evitar la Ceguera en México:

Study Start Date: December 2005
Estimated Study Completion Date: July 2006
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Proliferative diabetic retinopathy, vascular vein oclussion, choroidal neovascularization
  • Multifocal electroretinogram before intravitreal bevacizumab and at 1,3, and 6 months after treatment
  • Completely studies

Exclusion Criteria:

Complications

  • Tractional Detachment
  • Endophthalmitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00417833

Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Investigators
Principal Investigator: Myrian L Hernández, MD Asociación para Evitar la Ceguera en México
  More Information

ClinicalTrials.gov Identifier: NCT00417833     History of Changes
Other Study ID Numbers: APEC-0017
Study First Received: January 3, 2007
Last Updated: October 17, 2008

Additional relevant MeSH terms:
Neovascularization, Pathologic
Choroidal Neovascularization
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents

ClinicalTrials.gov processed this record on September 21, 2017